SATURDAY, OCTOBER 1, 2016

Thomas F. Schaible appointed project leader of Coronado Biosciences IBD efforts

Coronado Biosciences, Inc., announced on Tuesday Thomas F. Schaible joined the company as project leader for the research and development of Trichuris suis ova treatments for inflammatory bowel disease.

"We are excited that Dr. Schaible has joined us in developing TSO for IBD," Dr. Harlan F. Weisman, Coronado's chairman and CEO, said. "Dr. Schaible led the efforts at Johnson & Johnson in getting REMICADE approved for Crohn's disease and rheumatoid arthritis. His extensive development and regulatory experience in IBD and other autoimmune conditions will be instrumental to progressing TSO forward."

Coronado Biosciences is a biopharmaceutical company that focuses on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.

Schaible is known for his work at Janssen Biotech, where he was vice president of medical affairs. He was also an assistant professor of medicine and physiology at Albert Einstein College of Medicine in New York.

"We believe the fact that we are able to attract someone with Dr. Schaible's credentials is a testament of the interest in the hygiene hypothesis within the field of immunology and TSO's potential to be a game changer for patients with IBD and other autoimmune diseases," Weisman said.